Published in Neuro Oncol on January 12, 2017
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget (2017) 0.75
MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas? Neuro Oncol (2017) 0.75
Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors. Am J Surg Pathol (2017) 0.75
Investigation of brain tissue infiltration by medulloblastoma cells in an ex vivo model. Sci Rep (2017) 0.75
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med (2010) 3.98
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry (2007) 3.01
The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol (2004) 2.66
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol (2008) 2.61
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov (2014) 2.44
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A (2013) 2.15
The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell (2011) 1.92
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol (2011) 1.90
RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell (2013) 1.89
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell (2014) 1.88
Phosphorylation state of Olig2 regulates proliferation of neural progenitors. Neuron (2011) 1.83
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell (2015) 1.71
Allosteric activation of functionally asymmetric RAF kinase dimers. Cell (2013) 1.60
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc Natl Acad Sci U S A (2011) 1.44
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol (2014) 1.23
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. Sci Rep (2013) 1.12
RAF inhibitors that evade paradoxical MAPK pathway activation. Nature (2015) 1.12
Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol (2011) 1.09
p53 gene mutations in pediatric brain tumors. Med Pediatr Oncol (1995) 1.03
OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. J Neurooncol (2010) 0.89
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell (2015) 0.89
A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. J Vis Exp (2015) 0.80
First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. J Biomed Nanotechnol (2016) 0.77
Diversity of glial cell components in pilocytic astrocytoma. Neuropathology (2008) 0.77
Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol (2016) 0.76